Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming

 
• By Anju Ghangurde

After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.

Action Heats Up In the GLP-1 battleground • Source: Shutterstock

More from Business

More from Scrip